Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 32

recruiting
3 987
countries
28
conditions
2 109

642 trials match your criteria

Neurodermatitis

Not recruiting

Study on the Effects of Povorcitinib for Patients with Prurigo Nodularis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide

Bronchopulmonary aspergillosis

Not recruiting

Study on the Safety and Effectiveness of Opelconazole with Other Antifungal Treatments for Patients with Hard-to-Treat Lung Aspergillosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Opelconazole

Multiple sclerosis

Not recruiting

Study on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Frexalimab

Neoplasm

Not recruiting

Study on ANV600 and Pembrolizumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ANV600

Hepatic cirrhosis

Not recruiting

Study of Resmetirom in Patients with Well-compensated Non-alcoholic Steatohepatitis (NASH) Cirrhosis to Evaluate Effects on Liver Health

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Resmetirom

Primary progressive multiple sclerosis

Not recruiting

Study on Tolebrutinib for Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Tolebrutinib

Hormone receptor positive breast cancer

Not recruiting

Study on Palbociclib and Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib

Colorectal cancer metastatic+1

Not recruiting

Study of Encorafenib, Cetuximab, and Pembrolizumab for Patients with Untreated BRAF V600E-Mutant Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cetuximab

Acute graft versus host disease in intestine

Not recruiting

Study on MaaT013 for Treating Acute Gastrointestinal Graft-Versus-Host Disease in Patients Not Responding to Ruxolitinib

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Faecal Microbiota, Pooled

Multiple sclerosis relapse

Not recruiting

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Ofatumumab

Dermatitis atopic

Not recruiting

Study on the Effectiveness of Ruxolitinib Cream for Adults with Moderate Atopic Dermatitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib

Squamous cell carcinoma of head and neck

Not recruiting

Study on Adding Nivolumab to Cisplatin and Radiotherapy for High-Risk Patients with Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.